Photocure ASA 2025 AR2
The report highlights Photocure's financial and operational performance in 2025, achieving a 9% product revenue growth for Hexvix/Cysview to NOK 530.1 million and commercial EBITDA of NOK 28.7 million. The company expanded its active accounts in the U.S. by 22% to 384 and initiated direct sales in Spain. Photocure also advanced key strategic initiatives, including its partnership with Richard Wolf for a next-generation flexible blue light cystoscope and a collaboration with Intelligent Scopes Corporation to develop AI software for bladder cancer diagnostics. Additionally, the company received the prestigious Innovation Prize from the Norwegian Cancer Society.
Company: Photocure ASA
Sector: Manufacturing
Country: Norway
Year: 2025
Type: AR2
Pages: 62
Back to company
Photocure ASA
Annual Report
The report highlights Photocure's financial and operational performance in 2025, achieving a 9% product revenue growth for Hexvix/Cysview to NOK 530.1 million and commercial EBITDA of NOK 28.7 million. The company expanded its active accounts in the U.S. by 22% to 384 and initiated direct sales in Spain. Photocure also advanced key strategic initiatives, including its partnership with Richard Wolf for a next-generation flexible blue light cystoscope and a collaboration with Intelligent Scopes Corporation to develop AI software for bladder cancer diagnostics. Additionally, the company received the prestigious Innovation Prize from the Norwegian Cancer Society.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees